Biogen Inc. (BIIB) Q4 2025 (USD): adj. EPS 1.99 (exp. 1.62), Revenue 2.3bln (exp. 2.20bln)

Biogen's Q4 2025 results beat expectations significantly on both earnings per share and revenue, which likely reflects strong operational performance and may boost investor sentiment.

Newsquawk StaffPublished On the live feed at 6 more headlines followed before this page went public
Newsquawk headlinesUTC

Pandora (PNDORA DC) announces that BlackRock (BLK) now holds 6,727,166 shares (8.51% stake vs prev. 8.47%)

Tata Steel (TATASTEEL IS) Q3 Net income INR 26.9bln (exp. INR 25.3bln)

Biogen Inc. (BIIB) Q4 2025 (USD): adj. EPS 1.99 (exp. 1.62), Revenue 2.3bln (exp. 2.20bln)

ECB's Kocher says they don't see much strength in the EUR, adding that FX remains relatively stable recently

Centene Corporation (CNC) Q4 2025 (USD): Adj. EPS -1.19 (exp. -1.22), Revenue 49.7bln (exp. 48.39bln)

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.

GUIDANCE:

  • FY EPS view 15.25-16.25 (exp. 15.01)
Context

The upward revision in their FY EPS guidance also suggests confidence in sustained profitability moving forward, potentially impacting share price positively. This could have implications across the biotech sector, influencing peer performances and market valuations.

Related headlines

The whole workspace, free to try.

Try it free